In the context of the celebration of the tenth anniversary of the working group on biosimilar drugs of the European Union, around 280 delegates from 36 countries are participating since yesterday in the 13th EGA-EBG Conference in London to discuss key issues related to biosimilar medicines. The main topics of the conference include an assessment of the impact of biosimilars in improving access and supporting the sustainability of healthcare systems, as well as regulatory and market developments. In addition, all stakeholders will seek to shape the debate on increasing understanding and acceptance of biosimilars, a critical success factor for the sustainability of the biosimilars industry. biosimilar drugs.
The conference, which ends today, features leading global experts on biosimilar medicines regulation from the European Medicines Agency, the EMA Biosimilars Working Group, the US Food and Drug Administration (FDA), Health Canada, ANVISA, the World Health Organization and other national drug regulatory authorities to discuss the convergence of regulatory requirements.
Just before the start of the conference, Nick Haggar, President of the EGA, said that 'EBG and EGA partner companies are developing complex products such as biosimilar medicines to increase patient access and to make medicines more sustainable. health systems, in which 80% of the costs are linked to chronic diseases. These industries will be the main drivers of the sustainability of healthcare systems across Europe.'
You can follow the conference through the hashtag #EBGBIOS15 and follow the EGA accounts on Twitter, @egagenerics and @egabiosimilars
(Featured image: @andrewfbourgoin)
